Characterization of patients with cystic fibrosis presenting an indeterminate glucose tolerance (INDET)

详细信息    查看全文

• 作者：Adè ; le Coriati^a ; ^b ; Sophie Ziai^a ; ^b ; Mirna Azar^d ; Yves Berthiaume^a ; ^c ; ^d ; Ré ; mi Rabasa-Lhoret^a ; ^b ; ^c ; ^d ; ^{remi.rabasa-lhoret@ircm.qc.ca" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Cystic fibrosis ; Oral glucose tolerance test ; Indeterminate glucose tolerance ; Pulmonary function ; CFRD
• 刊名：Journal of Cystic Fibrosis
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：15
• 期：1
• 页码：127-132
• 全文大小：303 K

文摘

CFRD is preceded and associated with a significantly increased morbidity and mortality. We aimed to characterize a large newly established glucose tolerance subgroup named INDET (indeterminate; 1-h oral glucose tolerance test (OGTT) > 11.0 but 2 h-OGTT < 7.8 mmol/L) in adult patients with cystic fibrosis (CF).

Methods

All CF participants (n = 252, ≥ 18 yrs without CFRD) underwent a 2 h-OGTT with glucose and insulin sample measurements every 30 min. They were then classified as having either normal, impaired, or INDET glucose tolerance, or de novo CFRD. Other clinical characteristics were collected such as the BMI and pulmonary function.

Results

All groups were of similar age (P = 0.629) and BMI (P = 0.813). We found that the INDETs displayed decreased lung function comparable to de novo CFRD. OGTT-derived glucose or insulin secretion/sensitivity parameters cannot fully explain this observation.

Conclusions

Prospective studies are required to establish if the INDET-CF group can identify clinically relevant outcomes.